MAP Pharmaceuticals to Host Conference Call on Friday, December 19 to Discuss Worldwide Collaboration with AstraZeneca for UDB
You may join the call via telephone at 888-670-2248 (domestic) or 913-312-0980 (international). Access to the live webcast will be available via theInvestor Relations section of the Company's Website at www.mappharma.com. Areplay will also be available within 24 hours for at least seven daysfollowing the conference call.
About MAP Pharmaceuticals
MAP Pharmaceuticals, Inc. develops and plans to commercialize newtherapies for children and adults who suffer from chronic conditions that itbelieves are not adequately treated by currently available medicines. Thecompany applies its proprietary inhalation technologies to enhance thetherapeutic benefits and commercial attractiveness of proven drugs whileminimizing risk by capitalizing on their known safety, efficacy andcommercialization history. MAP Pharmaceuticals has two drug candidates inPhase 3 clinical trials. Unit Dose Budesonide is being developed for thepotential treatment of pediatric asthma, and MAP0004 is being developed forthe potential treatment of migraine. MAP Pharmaceuticals' pipeline alsoincludes a drug candidate in early clinical development for the treatment ofasthma and chronic obstructive pulmonary disease.
Additional information about MAP Pharmaceuticals can be found athttp://www.mappharma.com
SOURCE MAP Pharmaceuticals
You May Also Like